Uric acid (UA) is synthesized mainly in the liver, intestines, and vascular endothelium as the
end product of an exogenous purine from food and endogenously from damaged, dying …

This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA …

Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has
also been associated with the development of type 2 diabetes mellitus (T2DM) and …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes …

Postprandial hyperlipidemia showing postprandial increases in serum triglyceride (TG) is
associated with the development of atherosclerotic cardiovascular disease (ASCVD). To …

Abstract Purpose of Review To review the clinical trial data and underlying mechanistic
principles in support of the robust cardiovascular (CV) benefits, in particular, heart failure …

Introduction Dapagliflozin is a sodium–glucose cotransporter 2 inhibitor that improves
glycemic control in patients with type II diabetes mellitus which increasing urinary glucose …

Several medications and medication classes have been reported to affect the lipid profile.
Risk factors include elevated lipid levels at baseline and high cardiovascular (CV) risk …

Type-2 diabetes mellitus (DM) represents one of the most important risk factors for
cardiovascular diseases (CVD). Hyperglycemia and glycemic variability are not the only …